India will continue to produce generic HIV drugs, Commerce and Industry Minister says

NewsGuard 100/100 Score

"India will not compromise on drug licensing norms and [will] continue to produce generic drugs for free treatment to HIV-positive patients, Commerce and Industry Minister Anand Sharma said" on Wednesday, the IANS/Times of India reports.

"To make them available to all countries, India will also use the flexibilities allowed under TRIPS (trade-related aspects of intellectual property rights) to ensure that people living with HIV have access to all life-saving medicines," Sharma said, the newspaper adds (7/6).

UNAIDS Executive Director Michel Sidibe "welcomed the announcement that India would continue to make generic drugs to combat the disease and said the decision will save millions of lives," according to the U.N. News Centre. "India, together with Brazil, South Africa, China and Russia, must forge an alliance with other high-income countries to ensure that no single person in the world dies because they could not afford to buy life-saving medicines or health care," Sidibe said (7/6).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Increased coronary vessel wall thickness linked to heart dysfunction in asymptomatic HIV patients